Peter Rigsby

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6680604/publications.pdf

Version: 2024-02-01

74 papers	1,020 citations	516710 16 h-index	501196 28 g-index
74 all docs	74 docs citations	74 times ranked	1356 citing authors

#	Article	IF	Citations
1	An international collaborative study to assign value for Total Factor XIIIâ€Β Subunit Antigen to the WHO 1st International Standard for Factor XIII Plasma, (02/206): Communication from the ISTH SSC Subcommittee on Factor XIII and Fibrinogen. Journal of Thrombosis and Haemostasis, 2022, 20, 525-531.	3.8	2
2	An international collaborative study to establish the WHO 3rd International Standard for Thrombin: Communication from the ISTH SSC subcommittee on factor XIII and fibrinogen. Journal of Thrombosis and Haemostasis, 2021, 19, 852-858.	3.8	0
3	Saccharide dosage content of meningococcal polysaccharide conjugate vaccines determined using WHO International Standards for serogroup A, C, W, Y and X polysaccharides. Biologicals, 2021, 70, 53-58.	1.4	3
4	The First WHO International Standard for Adalimumab: Dual Role in Bioactivity and Therapeutic Drug Monitoring. Frontiers in Immunology, 2021, 12, 636420.	4.8	7
5	The First WHO International Standard for Harmonizing the Biological Activity of Bevacizumab. Biomolecules, 2021, 11, 1610.	4.0	2
6	Differences in Antigenic Structure of Inactivated Polio Vaccines Made From Sabin Live-Attenuated and Wild-Type Poliovirus Strains: Impact on Vaccine Potency Assays. Journal of Infectious Diseases, 2020, 221, 544-552.	4.0	14
7	Expansion of the 1st WHO international standard for antiserum to respiratory syncytial virus to include neutralisation titres against RSV subtype B: An international collaborative study. Vaccine, 2020, 38, 800-807.	3.8	6
8	A new WHO reference reagent for activated blood coagulation factor X (FXa), human (15/102). Journal of Thrombosis and Haemostasis, 2020, 18, 255-257.	3.8	1
9	The first World Health Organization International Standard for in vitro biological activity of darbepoetin. Biologicals, 2020, 63, 33-38.	1.4	1
10	Development and Assessment of a Pooled Serum as Candidate Standard to Measure Influenza A Virus Group 1 Hemagglutinin Stalk-Reactive Antibodies. Vaccines, 2020, 8, 666.	4.4	6
11	Development of the first reference antibody panel for qualification and validation of cytokine release assay platforms â€“ Report of an international collaborative study. Cytokine: X, 2020, 2, 100042.	1.4	6
12	Establishment of a WHO Reference Reagent for anti-Mullerian hormone. Reproductive Biology and Endocrinology, 2020, 18, 86.	3.3	13
13	The Use of Next-Generation Sequencing for the Quality Control of Live-Attenuated Polio Vaccines. Journal of Infectious Diseases, 2020, 222, 1920-1927.	4.0	8
14	Evaluation of a standardised Vi poly-l-lysine ELISA for serology of Vi capsular polysaccharide antibodies. Biologicals, 2020, 66, 21-29.	1.4	6
15	An international collaborative study to establish the WHO 4th International Standard for Streptokinase: Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2020, 18, 1501-1505.	3.8	3
16	Continued provision of WHO International Standards for total and free PSA: Content and commutability of replacement preparations. Clinical Biochemistry, 2019, 71, 58-66.	1.9	6
17	The third international standard for antiâ€Ð immunoglobulin: international collaborative study to evaluate candidate preparations. Vox Sanguinis, 2019, 114, 740-748.	1.5	2
18	Harmonization of Zika neutralization assays by using the WHO International Standard for anti-Zika virus antibody. Npj Vaccines, 2019, 4, 42.	6.0	13

#	Article	IF	Citations
19	Evaluation of a capture antigen ELISA for the characterisation of tetanus vaccines for veterinary use. Biologicals, 2019, 61, 8-14.	1.4	9
20	Comparison of Serologic Assays for Middle East Respiratory Syndrome Coronavirus. Emerging Infectious Diseases, 2019, 25, 1878-1883.	4.3	16
21	Comparison of Volumetric and Beadâ€Based Counting of CD34 Cells by Singleâ€Platform Flow Cytometry. Cytometry Part B - Clinical Cytometry, 2019, 96, 508-513.	1.5	13
22	Establishment of the WHO 2nd International Standard Factor V, plasma (16/374): communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2019, 17, 695-697.	3.8	0
23	A WHO Reference Reagent for lupus (anti-dsDNA) antibodies: international collaborative study to evaluate a candidate preparation. Annals of the Rheumatic Diseases, 2019, 78, 1677-1680.	0.9	16
24	The first World Health Organization International Standard for infliximab products: A step towards maintaining harmonized biological activity. MAbs, 2019, 11, 13-25.	5.2	16
25	Evaluation of two WHO First International Standards for Vi polysaccharide from Citrobacter freundii and Salmonella enterica subspecies enterica serovar Typhi. Biologicals, 2019, 57, 34-45.	1.4	6
26	Establishment of the 1st WHO International Standard for anti-EV71 serum (Human). Biologicals, 2018, 53, 39-50.	1.4	7
27	International standards for monoclonal antibodies to support pre- and post-marketing product consistency: Evaluation of a candidate international standard for the bioactivities of rituximab. MAbs, 2018, 10, 129-142.	5.2	16
28	Establishment of the first WHO International Standard for antiserum to Respiratory Syncytial Virus: Report of an international collaborative study. Vaccine, 2018, 36, 7641-7649.	3.8	24
29	Calibration of the 7th British Working Standard for factors II, IX and X, concentrate. Biologicals, 2018, 56, 63-66.	1.4	0
30	Establishment of the first International Standard for human anti-typhoid capsular Vi polysaccharide IgG. Biologicals, 2018, 56, 29-38.	1.4	20
31	Establishment of the World Health Organization First International Standard for Factor XII, Plasma, Human. Frontiers in Medicine, 2018, 5, 46.	2.6	4
32	Recommendations of the VAC2VAC workshop on the design of multi-centre validation studies. Biologicals, 2018, 52, 78-82.	1.4	5
33	Comparison of platform technologies for assaying antibody to Ebola virus. Vaccine, 2017, 35, 1347-1352.	3.8	28
34	Evaluation of candidate international standards for meningococcal serogroups A and X polysaccharide. Biologicals, 2017, 47, 33-45.	1.4	8
35	Preparation, calibration and evaluation of the First International Standard for human C-peptide. Clinical Chemistry and Laboratory Medicine, 2017, 55, 1224-1233.	2.3	7
36	Establishment of the first WHO International Standard for etanercept, a TNF receptor II Fc fusion protein: Report of an international collaborative study. Journal of Immunological Methods, 2017, 447, 14-22.	1.4	11

#	Article	IF	Citations
37	Establishment of the World Health Organization 2nd International Standard for Factor XI, Plasma, Human. Frontiers in Medicine, 2017, 4, 28.	2.6	4
38	The establishment of a WHO Reference Reagent for anti-malaria (Plasmodium falciparum) human serum. Malaria Journal, 2017, 16, 314.	2.3	31
39	Development of an in vitro Biochemical Assay System for the Measurement of Residual Toxin Activities in Pertussis Toxin Containing Vaccines. Journal of Vaccines & Vaccination, 2017, 08, .	0.3	1
40	Establishment of the first WHO Erythropoietin antibody reference panel: Report of an international collaborative study. Journal of Immunological Methods, 2016, 435, 32-42.	1.4	9
41	Collaborative study for the calibration of a replacement International Standard for diphtheria toxoid for use in flocculation test. Biologicals, 2016, 44, 556-566.	1.4	2
42	Establishment of replacement International Standard 13/132 for human antibodies to Toxoplasma gondii. Biologicals, 2016, 44, 448-455.	1.4	1
43	An International Standard for holotranscobalamin (holoTC): international collaborative study to assign a holoTC value to the International Standard for vitamin B12 and serum folate. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1467-1472.	2.3	7
44	Establishment of the first international standard for PEGylated granulocyte colony stimulating factor (PEG-G-CSF): Report of an international collaborative study. Journal of Immunological Methods, 2015, 416, 17-28.	1.4	12
45	International collaborative study for establishment of the 2nd WHO International Standard for Haemophilus influenzae type b polysaccharide. Biologicals, 2015, 43, 492-503.	1.4	0
46	The establishment of sub-strain specific WHO Reference Reagents for BCG vaccine. Vaccine, 2014, 32, 6390-6395.	3.8	18
47	A novel Enzyme-Linked Immuno-Sorbent Assay (ELISA) for the quantification of total and free polysaccharide in Haemophilus influenzae bâ€“Tetanus toxoid conjugate vaccines in monovalent and combined vaccine formulations. Biologicals, 2014, 42, 29-33.	1.4	9
48	Calibration and commutability assessment of the 1st International Standard for Diphtheria Antitoxin Human. Biologicals, 2013, 41, 384-392.	1.4	5
49	Evaluation of a candidate International Standard for Meningococcal Group C polysaccharide. Biologicals, 2012, 40, 353-363.	1.4	14
50	InÂvitro antigen ELISA for quality control of tetanus vaccines. Biologicals, 2012, 40, 466-472.	1.4	37
51	Evaluation of an inÂvitro assay system as a potential alternative to current histamine sensitization test for acellular pertussis vaccines. Biologicals, 2012, 40, 456-465.	1.4	13
52	A functional dual-coated (FDC) microtiter plate method to replace the botulinum toxin LD50 test. Analytical Biochemistry, 2012, 425, 28-35.	2.4	29
53	Report of an International collaborative study to establish the first WHO reference reagents for BCG vaccines of three different sub-strains. Vaccine, 2011, 29, 512-518.	3.8	20
54	Animal Refinement and Reduction: Alternative Approaches for Potency Testing of Diphtheria and Tetanus Vaccines. Procedia in Vaccinology, 2011, 5, 200-212.	0.4	15

#	Article	IF	Citations
55	EUVAC.NET collaborative study: Evaluation and standardisation of serology for diagnosis of pertussis. Journal of Immunological Methods, 2011, 372, 137-145.	1.4	21
56	Collaborative study for the calibration of a replacement International Standard for Tetanus Toxoid Adsorbed. Biologicals, 2011, 39, 404-416.	1.4	5
57	Collaborative study for the calibration of a replacement international standard for diphtheria toxoid adsorbed. Biologicals, 2010, 38, 529-538.	1.4	6
58	Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. Blood, 2010, 116, e111-e117.	1.4	141
59	Immunogenicity and thermal stability of a combined vaccine against Haemophilus influenzae type b and Neisseria meningitidis serogroup C diseases. Vaccine, 2010, 28, 6228-6234.	3.8	7
60	Transferability of dermal temperature histamine sensitization test for estimation of pertussis toxin activity in vaccines. Hum Vaccin, 2009, 5, 166-171.	2.4	11
61	Development and use of a novel in vitro assay for testing of diphtheria toxoid in combination vaccines. Journal of Immunological Methods, 2009, 350, 142-149.	1.4	35
62	Evaluation of two human plasma pools as candidate international standard preparations for syphilitic antibodies. Biologicals, 2009, 37, 245-251.	1.4	1
63	An improved method for development of toxoid vaccines and antitoxins. Journal of Immunological Methods, 2008, 337, 42-48.	1.4	41
64	Report of an international collaborative study to establish the suitability of using modified ATP assay for viable count of BCG vaccine. Vaccine, 2008, 26, 4754-4757.	3.8	14
65	A Retrospective Study on the Quality of Haemophilus Influenzae Type B Vaccines Used in the U.K. Between 1996 and 2004. Hum Vaccin, 2007, 3, 176-182.	2.4	10
66	Evaluation of the saccharide content and stability of the first WHO International Standard for Haemophilus influenzae b capsular polysaccharide. Biologicals, 2007, 35, 235-245.	1.4	22
67	Investigation in a Model System of the Effects of Combinations of Anthrax and Pertussis Vaccines Administered to Service Personnel in the 1991Gulf War. Hum Vaccin, 2005, 1, 165-169.	2.4	13
68	Evaluation of a Candidate International Standard Preparation for Human Anti- Toxoplasma Immunoglobulin G. Journal of Clinical Microbiology, 2004, 42, 5133-5138.	3.9	25
69	A multicentre assessment of the endogenous thrombin potential using a continuous monitoring amidolytic technique. British Journal of Haematology, 2003, 123, 335-341.	2.5	13
70	A national quality assessment scheme for counting residual leucocytes in unfixed leucodepleted products: the effect of standardisation and 48 hour storage. Transfusion and Apheresis Science, 2002, 26, 73-81.	1.0	5
71	A platelet quality assessment scheme for comparing the performance of quality monitoring laboratories in the UK National Blood Service. Transfusion and Apheresis Science, 2002, 26, 83-90.	1.0	2
72	Standardisation of Factor VIII and von Willebrand Factor in Plasma: Calibration of the 4th International Standard (97/586). Thrombosis and Haemostasis, 2001, 85, 634-638.	3.4	29

#	Article	IF	Citations
73	International Collaborative Study: Evaluation of Proposed International Reference Reagent of Pertussis Antiserum (Mouse) 97/642. Biologicals, 2001, 29, 137-148.	1.4	10
74	Reference Reagents for Prostate-specific Antigen (PSA): Establishment of the First International Standards for Free PSA and PSA (90:10). Clinical Chemistry, 2000, 46, 1310-1317.	3.2	77